image header

News Releases

News Releases

Aug 1, 2022

ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma Read more

Jun 29, 2022

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia Read more

Jun 3, 2022

ALX Oncology Announces Evorpacept Clinical Program Updates Read more

Jun 1, 2022

ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference Read more

May 9, 2022

ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Read more

Apr 12, 2022

ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors Read more

Mar 2, 2022

ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer Read more

Feb 28, 2022

ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones Read more

Jan 27, 2022

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer Read more

Jan 10, 2022

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022 Read more

Displaying 11 - 20 of 21